Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 1/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 14/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24072837 | 0.91 | AGPAT2 (0.37) | AGPAT2CRHR1MEN1KMT2AFFAR4 | |
| SCHEMBL30370028 | 0.91 | AGPAT2 (0.37) | AGPAT2CRHR1MEN1KMT2AFFAR4 | |
| SCHEMBL25304785 | 0.90 | ADORA2A (0.36) | — | |
| SCHEMBL30370537 | 0.88 | AGPAT2 (0.38) | AGPAT2CRHR1MEN1KMT2AFFAR4 | |
| SCHEMBL31017677 | 0.88 | AGPAT2 (0.38) | AGPAT2CRHR1MEN1KMT2AFFAR4 | |
| SCHEMBL27418620 | 0.88 | AGPAT2 (0.38) | AGPAT2CRHR1MEN1KMT2AFFAR4 | |
| SCHEMBL24073580 | 0.88 | AGPAT2 (0.38) | AGPAT2CRHR1MEN1KMT2AFFAR4 | |
| SCHEMBL24072840 | 0.88 | AGPAT2 (0.38) | AGPAT2CRHR1MEN1KMT2AFFAR4 | |
| SCHEMBL24073578 | 0.88 | AGPAT2 (0.38) | AGPAT2CRHR1MEN1KMT2AFFAR4 | |
| SCHEMBL25260209 | 0.88 | ACKR3 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4157834-B1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LTD (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | USP30, UQCRC1, NDUFAF1 | AGPAT2 3809/4885CRHR1 3882/4885MEN1 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.